

Subject ID	MCN
US3492243	(b) (6)
Preferred Term:	COVID-19
Treatment Assignment:	mRNA-1273

This 50-year-old, white, Hispanic or Latino male subject experienced a serious event of COVID-19. The subject's medical history did not include any health risk factors for severe COVID 19. The subject received his first dose on 23 Sep 2020 and 2nd dose on 21 Oct 2020.

The subject had SARS-CoV-2 exposure from a positive family member and on 06 Nov 2020, the subject began quarantine. From 07 Nov 2020 through 08 Nov 2020, the subject complained of fatigue. A nasopharyngeal rapid polymerase chain reaction for SARS-CoV-2 performed was positive but confirmation of the result is pending. On 18 Nov 2020, symptom included mild fatigue. Vitals included blood pressure 148/89 mmHg, oxygen saturation 100 %, temperature 98.8 degrees Fahrenheit, pulse 77 beats/min and respirations 18 breaths/min. To date this case has not been assessed as severe but the Investigator's assessment is not complete. Action taken with study drug was not applicable as the subject had already received both scheduled doses. At the time of this report, the event had not yet resolved.